GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges

Modern lifestyle diseases remain a persistent challenge in healthcare. Currently, about 422 million people worldwide are affected by diabetes, while 1 in 8 people are living with obesity. The development of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has marked a significant milestone in tr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Patrycja Kupnicka, Małgorzata Król, Justyna Żychowska, Ryszard Łagowski, Eryk Prajwos, Anna Surówka, Dariusz Chlubek
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Pharmaceuticals
Subjects:	glucagon-like peptide-1 GLP-1 receptor agonists obesity cancer inflammation
Online Access:	https://www.mdpi.com/1424-8247/17/11/1470
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
by: Miodrag Janić, et al.
Published: (2024-12-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
by: Haijun Wan, et al.
Published: (2024-11-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes
by: Kevin Y. Heo, BS, et al.
Published: (2024-12-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
by: Gisella Figlioli, et al.
Published: (2024-12-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
by: Gentinetta S, et al.
Published: (2024-12-01)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024-11-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
by: Hui Guo, et al.
Published: (2024-11-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
by: Sofía Echeverry-Guerrero, et al.
Published: (2024-11-01)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
by: Yi-Hsuan Lin, et al.
Published: (2022-12-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
by: Tohada M. AL-Noshokaty, et al.
Published: (2025-06-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
by: Zhiyuan Cheng, et al.
Published: (2024-10-01)

Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
by: Kosuke Sawami, et al.
Published: (2024-11-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Induced Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus
by: Koji Kikkawa, et al.
Published: (2021-09-01)

Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control studyResearch in context
by: Julien Bezin, et al.
Published: (2025-02-01)